埃克替尼一线治疗晚期非小细胞肺癌的临床评价

1.Department of Oncology, the Second Affiliated Hospital of Dalian Medical University，Dalian 116031，China; 2. Department of Oncology,the First Affiliated Hospital of Dalian Medical University，Dalian 116011，China

关键词:  非小细胞肺癌  埃克替尼  近期疗效  安全性

Key words:  non-small cell lung cancer(NSCLC)  icotinib  short-term effect  safety

摘要:

目的　观察埃克替尼一线治疗晚期非小细胞肺癌（NSCLC）患者的近期疗效及安全性。方法　21例晚期NSCLC患者，给予埃克替尼125 mg, 口服, 3次/d。观察客观有效率、临床症状缓解情况、不良反应，直至出现疾病进展或不可耐受的不良反应。结果　完全缓解（CR）0例,部分缓解（PR）9例,稳定（SD）9例，进展（PD）3例，客观有效率（ORR）42.9 %，疾病控制率（DCR）85.7%，中位无进展生存期（PFS）为 7.2个月。不良反应主要为皮疹和腹泻。结论　埃克替尼一线治疗晚期NSCLC具有较好的近期疗效及安全性，耐受性良好。

Abstract:

Objective 〖WTBZ〗To observe the efficacy, safety in treatment with icotinib as first-line therapy with advanced non-small cell lung cancer(NSCLC). 〖WTHZ〗Methods 〖WTBZ〗Twenty-one patients with advanced NSCLC were enrolled in the study. All the patients treated with icotinib 125 mg, po, three times a day .The response rate,clinical symptom and toxicity were observed until progression or unacceptable toxicity. 〖WTHZ〗Results 〖WTBZ〗No patient appeared complete response, nine patients appeared partial response, nine patients appeared stable disease and three patients had progressive disease. The objective response rate was 42.9 %, and the disease control rate was 85.7 %. Median Time to Progress was 7.2 months. The main toxicity were skin rash and diarrhea. 〖WTHZ〗Conclusion〖WTBZ〗 Icotinib as first-ling therapy is an effective in the treatmean of advanced non-small cell lung cancer. All of patients are well-tolerated.